Advertisement

International Urology and Nephrology

, Volume 50, Issue 12, pp 2245–2253 | Cite as

Association between MCP-1 2518 A>G gene polymorphism and chronic kidney disease

  • Song MaoEmail author
  • Liangxia WuEmail author
Nephrology - Original Paper
  • 47 Downloads

Abstract

Monocyte chemoattractant protein-1 (MCP-1) is involved in the pathogenesis of chronic kidney diseases (CKD). MCP-1 2518 A>G gene polymorphism is associated with MCP-1 status. We performed a meta-analysis to assess the association between MCP-1 2518 A>G gene polymorphism and CKD risk. The eligible studies regarding the relationship between MCP-1 2518 A>G gene polymorphism and CKD risk were searched through electronic databases. The pooled odds ratios (ORs) and its 95% confidence intervals (CIs) were calculated by using a fixed-effects model, or in the presence of heterogeneity, a random-effects model. A total of 2415 cases and 2011 controls were recruited in our investigation. A allele/GG genotype was not associated with CKD risk in overall populations, Asians, Caucasians, and Africans. AA/AG genotype was not associated with the risk of CKD in overall populations, Asians, Caucasians, and Africans. AA genotype was associated with a lower risk of CKD in Caucasians (OR 0.816, 95% CI 0.703–0.947). AG genotype was associated with a higher risk of CKD in Caucasians (OR 1.230, 95% CI 1.042–1.452). There was no marked publication bias. In conclusion, AA genotype may be a protective factor against CKD susceptibility in Caucasians. AG genotype may be a risk factor for CKD risk in Caucasians. However, more studies are needed in the future.

Keywords

MCP-1 2518 A>G Gene polymorphism Chronic kidney diseases 

Notes

Acknowledgements

This study was supported by Grant from the National Natural Science Foundation of China (Grant Number 81600578) and weak discipline construction of Shanghai health and family planning commission (Grant Number 2016ZB0102-03).

Compliance with ethical standards

Conflict of interest

There is no conflict of interest for all authors.

References

  1. 1.
    Yaseen A, Tresa V, Lanewala AA, Hashmi S, Ali I, Khatri S et al (2017) Acute kidney injury in idiopathic nephrotic syndrome of childhood is a major risk factor for the development of chronic kidney disease. Ren Fail 39:323–327CrossRefGoogle Scholar
  2. 2.
    Visconti L, Benvenga S, Lacquaniti A, Cernaro V, Bruzzese A, Conti G et al (2016) Lipid disorders in patients with renal failure: role in cardiovascular events and progression of chronic kidney disease. J Clin Transl Endocrinol 6:8–14PubMedPubMedCentralGoogle Scholar
  3. 3.
    Mahmoodnia L, Tamadon MR (2017) On the occasion of world kidney day 2017; obesity and its relationship with chronic kidney disease. J Nephropathol 6:105–109CrossRefGoogle Scholar
  4. 4.
    Bergman S, Key BO, Kirk KA, Warnock DG, Rostant SG (1996) Kidney disease in the first- degree relatives of African-Americans with hypertensive end-stagerenal disease. Am J Kidney Dis 27:341–346CrossRefGoogle Scholar
  5. 5.
    Akchurin OM, Kaskel F (2015) Update on inflammation in chronic kidney disease. Blood Purif 39:84–92CrossRefGoogle Scholar
  6. 6.
    Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G (2005) Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68:237–245CrossRefGoogle Scholar
  7. 7.
    Jia T, Serbina NV, Brandl K, Zhong MX, Leiner IM, Charo IF et al (2008) Additive roles for MCP-1 and MCP-3 in CCR2-mediated recruitment of inflammatory monocytes during Listeria monocytogenes infection. J Immunol 180:6846–6853CrossRefGoogle Scholar
  8. 8.
    Kolattukudy PE, Niu J (2012) Inflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/CCR2 pathway. Circ Res 110:174–189CrossRefGoogle Scholar
  9. 9.
    Wu CC, Chen JS, Lu KC, Chen CC, Lin SH, Chu P, Sytwu HK, Lin YF (2010) Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin Chim Acta 411:700–704CrossRefGoogle Scholar
  10. 10.
    Fukami A, Yamagishi S, Adachi H, Matsui T, Yoshikawa K, Ogata K, Kasahara A, Tsukagawa E, Yokoi K, Imaizumi T (2011) High white blood cell count and low estimated glomerular filtration rate are independently associated with serum level of monocyte chemoattractant protein-1 in a general population. Clin Cardiol 34:189–194CrossRefGoogle Scholar
  11. 11.
    Gregg LP, Tio MC, Li X, Adams-Huet B, de Lemos JA, Hedayati SS (2018) Association of monocyte chemoattractant protein-1 with death and atherosclerotic events in chronic kidney disease. Am J Nephrol 47:395–405CrossRefGoogle Scholar
  12. 12.
    Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K (2000) Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 58:684–690CrossRefGoogle Scholar
  13. 13.
    Hong SB, Jin SY, Park HJ, Jung JH, Sim WY (2006) Analysis of the monocyte chemoattractant protein 1 -2518 promoter polymorphism in Korean patients with alopecia areata. J Korean Med Sci 21:90–94CrossRefGoogle Scholar
  14. 14.
    Zakharyan R, Boyajyan A, Arakelyan A, Melkumova M, Mrazek F, Petrek M (2012) Monocyte chemoattractant protein-1 in schizophrenia: -2518A/G genetic variant and protein levels in Armenian population. Cytokine 58:351–354CrossRefGoogle Scholar
  15. 15.
    Joo KW, Hwang YH, Kim JH, Oh KH, Kim H, Shin HD et al (2007) MCP-1 and RANTES polymorphisms in Korean diabetic end-stage renal disease. J Korean Med Sci 22:611–615CrossRefGoogle Scholar
  16. 16.
    Moon JY, Jeong L, Lee S, Jeong K, Lee T, Ihm CG et al (2007) Association of polymorphisms in monocyte chemoattractant protein-1 promoter with diabetic kidney failure in Korean patients with type 2 diabetes mellitus. J Korean Med Sci 22:810–814CrossRefGoogle Scholar
  17. 17.
    Buraczynska M, Bednarek-Skublewska A, Buraczynska K, Ksiazek A (2008) Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for cardiovascular disease in hemodialyzed patients. Cytokine 44:361–365CrossRefGoogle Scholar
  18. 18.
    Krichen H, Khazen D, Sfar I, Ben Abdallah T, Bardi R, Jendoubi-Ayed S et al (2011) Genetic polymorphisms of inflammatory molecules in Tunisian kidney transplantation. Transpl Proc 43:433-436CrossRefGoogle Scholar
  19. 19.
    Ksiaa Cheikh Rouhou L, Gorgi YL, Skhiri HA, Aouadi H, Ayed SJ, Sfar I et al (2011) Chemokine and chemokine receptor gene polymorphism in Tunisian hemodialysis patients with HCV infection. Arab J Nephrol Transplant 4:117–124PubMedGoogle Scholar
  20. 20.
    Grzegorzewska AE, Pajzderski D, Sowińska A, Jagodziński PP (2014) Polymporphism of monocyte chemoattractant protein 1 (MCP1 -2518 A/G) and responsiveness to hepatitis B vaccination in hemodialysis patients. Pol Arch Med Wewn 124:10–18PubMedGoogle Scholar
  21. 21.
    Bagci B, Bagci G, Candan F, Ozdemir O, Sezgin I (2015) The protective effect of MCP-1 -2518 A>G promoter polymorphism in Turkish chronic renal failure patients requiring long-term hemodialysis. Int Urol Nephrol 47:551–556CrossRefGoogle Scholar
  22. 22.
    Besbas N, Kalyoncu M, Cil O, Ozgul RK, Bakkaloglu A, Ozaltin F (2015) MCP1 2518 A/G polymorphism affects progression of childhood focal segmental glomerulosclerosis. Ren Fail 37:1435–1439CrossRefGoogle Scholar
  23. 23.
    Raina P, Matharoo K, Bhanwer AJ (2015) Monocyte chemoattractant protein-1 (MCP-1)-2518 A> G polymorphism and susceptibility to type 2 diabetes (T2D) and end stage renal disease (ESRD) in the North-West Indian population of Punjab. Ann Hum Biol 42:276–282CrossRefGoogle Scholar
  24. 24.
    Dounousi E, Koliousi E, Papagianni A, Ioannou K, Zikou X, Katopodis K et al (2012) Mononuclear leukocyte apoptosis and inflammatory markers in patients with chronic kidney disease. Am J Nephrol 36:531–536CrossRefGoogle Scholar
  25. 25.
    Lin HY, Chang KT, Hung CC, Kuo CH, Hwang SJ, Chen HC et al (2014) Effects of the mTOR inhibitor rapamycin on monocyte-secreted chemokines. BMC Immunol 15:37CrossRefGoogle Scholar
  26. 26.
    Moledina DG, Isguven S, McArthur E, Thiessen-Philbrook H, Garg AX, Shlipak M et al (2017) Plasma monocyte chemotactic protein-1 is associated with acute kidney injury and death after cardiac operations. Ann Thorac Surg 104:613–620CrossRefGoogle Scholar
  27. 27.
    Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN (2005) Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 16:467–473CrossRefGoogle Scholar
  28. 28.
    Keeney M, Waters H, Barcay K, Jiang X, Yao Z, Pajarinen J, Egashira K, Goodman SB, Yang F (2013) Mutant MCP-1 protein delivery from layer-by-layer coatings on orthopedic implants to modulate inflammatory response. Biomaterials 34:10287–10295CrossRefGoogle Scholar
  29. 29.
    Fenoglio C, Galimberti D, Lovati C, Guidi I, Gatti A, Fogliarino S et al (2004) MCP-1 in Alzheimer’s disease patients: A-2518G polymorphism and serum levels. Neurobiol Aging 25:1169–1173CrossRefGoogle Scholar
  30. 30.
    Namlı Kalem M, Akgun N, Kalem Z, Bakirarar B, Celik T (2017) Chemokine (C-C motif) ligand-2 (CCL2) and oxidative stress markers in recurrent pregnancy loss and repeated implantation failure. J Assist Reprod Genet 34:1501–1506CrossRefGoogle Scholar
  31. 31.
    Zoja C, Corna D, Locatelli M, Rottoli D, Pezzotta A, Morigi M et al (2015) Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease. Nephron 129:52–61CrossRefGoogle Scholar
  32. 32.
    Serwin NM, Wiśniewska M, Jesionowska A, Skwirczyńska E, Marcinowska Z, Dołęgowska B (2016) Serum levels of 12 renal function and injury markers in patients with glomerulonephritis. Pol Arch Med Wewn 126:483–493PubMedGoogle Scholar
  33. 33.
    Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M et al (2010) Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis 56:883–895CrossRefGoogle Scholar
  34. 34.
    Tabara Y, Kohara K, Yamamoto Y, Igase M, Nakura J, Kondo I et al (2003) Polymorphism of the monocyte chemoattractant protein (MCP-1) gene is associated with the plasma level of MCP-1 but not with carotid intima-media thickness. Hypertens Res 26:677–683CrossRefGoogle Scholar
  35. 35.
    Davis TM, Makepeace AE, Ellard S, Colclough K, Peters K, Hattersley A et al (2017) The prevalence of monogenic diabetes in Australia: the Fremantle Diabetes Study Phase II. Med J Aust 207:344–347CrossRefGoogle Scholar
  36. 36.
    Yang P, Xiao Y, Luo X, Zhao Y, Zhao L, Wang Y et al (2017) Inflammatory stress promotes the development of obesity-related chronic kidney disease via CD36 in mice. J Lipid Res 58:1417–1427CrossRefGoogle Scholar
  37. 37.
    Umare VD, Pradhan VD, Rajadhyaksha AG, Ghosh K, Nadkarni AH (2017) A functional SNP MCP-1 (-2518A/G) predispose to renal disorder in Indian Systemic Lupus Erythematosus patients. Cytokine 96:189–194CrossRefGoogle Scholar
  38. 38.
    Su N, Li HY, Huang MF, Jiang ZP, Zhou TB (2015) Association of monocyte chemoattractant protein-1 2518G/A gene polymorphism with diabetic nephropathy risk. J Recept Signal Transduct Res 35:94–97CrossRefGoogle Scholar
  39. 39.
    Piotrowski P, Lianeri M, Gasik R, Roszak A, Olesińska M, Jagodziński PP (2010) Monocyte chemoattractant protein-1 -2518 A/G single nucleotide polymorphism might be associated with renal disease and thrombocytopenia of SLE. J Biomed Biotechnol 2010:130265CrossRefGoogle Scholar
  40. 40.
    Tesch GH (2008) MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 294:F697–F701CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Department of PediatricsShanghai Jiao Tong University Affiliated Sixth People’s HospitalShanghaiChina

Personalised recommendations